Omnicell, Inc.
OMCLHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframePart of the healthcare sector, Omnicell, Inc. (OMCL) is listed under Health Information Services. With a market capitalization of $1.72B, it sits in small-cap territory. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
Market Cap
$1.72B
Beta
0.99
P/E (TTM)
44.41
P/E (Fwd)
18.37
EPS (TTM)
$0.85
EPS (Fwd)
$2.06
ROE
3.1%
ROA
1.5%
Cash
$292.2M
Total Debt
$200.0M
Free CF
$134.2M
52W Change
21.4%
Annual Financials
Cash vs Debt
Where OMCL stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, OMCL finished 4.68% below its 150-day moving average ($38.24) and 8.39% below its 200-day moving average ($39.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OMCL overbought or oversold?
At the October 14, 2026 close, OMCL's RSI(14) was 73.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $292.2M in cash and $200.0M in debt, OMCL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $134.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 3.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.13B (2021) to $1.18B (2025).
Investors considering Omnicell, Inc. should weigh the typical risks associated with OMCL's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Omnicell, Inc. and its sector.